Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transforming growth factor beta receptor 1 (TGFBR1) is a membrane-bound serine/threonine protein kinase that forms part of the TGF-β receptor complex. It functions as a critical component in the TGF-β signaling pathway, which regulates numerous cellular processes including proliferation, differentiation, motility, adhesion, and apoptosis. When TGF-β ligand binds to the type II receptor (TGFBR2), TGFBR1 is recruited to form a heteromeric complex. The constitutively active TGFBR2 then phosphorylates and activates TGFBR1, which in turn phosphorylates downstream SMAD proteins (primarily SMAD2 and SMAD3). These phosphorylated SMADs associate with SMAD4 and translocate to the nucleus where they regulate gene expression. TGFBR1 is involved in both canonical (SMAD-dependent) and non-canonical (SMAD-independent) signaling pathways. Mutations in the TGFBR1 gene have been associated with Loeys-Dietz aortic aneurysm syndrome. Animal studies have shown that TGFBR1 plays a critical role in female reproductive tract function, with knockout mice exhibiting infertility and abnormal uterine development. Several inhibitors targeting TGFBR1 have been developed, including GW-788388, LY-2109761, Galunisertib, SB-431542, and SB-525334, which may have therapeutic potential in conditions where TGF-β signaling is dysregulated, such as fibrosis and certain cancers.
TGFBR1 functions through both canonical (SMAD-dependent) and non-canonical (SMAD-independent) pathways. Canonical pathway: 1. TGF-β binds to TGF-β type II receptor (TGFBR2) 2. TGFBR2 recruits TGFBR1 into a heteromeric complex 3. TGFBR1 is phosphorylated by the constitutively active TGFBR2 4. Activated TGFBR1 phosphorylates SMAD2/3 5. Phosphorylated SMAD2/3 associates with SMAD4 6. The SMAD complex translocates to the nucleus 7. The complex regulates transcription of TGF-β-regulated genes. Non-canonical pathway: - Induces TRAF6 autoubiquitination leading to MAP3K7 ubiquitination and activation to trigger apoptosis - Regulates epithelial to mesenchymal transition through PARD6A phosphorylation and activation.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transforming growth factor beta receptor 1 (TGFBR1).